EXAS Stock Recent News
EXAS LATEST HEADLINES
ST. LOUIS--(BUSINESS WIRE)--Geneoscopy announced that Exact Sciences has withdrawn its motion for a preliminary injunction regarding the '781 patent and the ‘746 patent.
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. Wells Fargo Healthcare Conference, Boston Fireside chat on Wednesday, September 3, 2025 at 1:30 p.m. ET Baird Global Healthcare Conference, New York Fireside chat on Tuesday, September 9, 2025 at 10:50 a.m. ET The webcast can be acces.
Exact Sciences tops on Q2 earnings and revenue estimates and raises the 2025 outlook, but shares slide 8% after results.
Cathie Wood is one of the country's best known growth investors, but sometimes, she acts like an umbrella-toting value investor. The Ark Invest co-founder, CEO, and chief investment officer is often adding to some of her sinking positions on any given market day, and that's exactly what she did on the final trading day of last week.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Exact Sciences Corp. EXAS on Thursday reported a second-quarter 2025 EPS loss of 1 cent, up from a 9-cent loss a year ago, beating the analyst consensus loss estimate of 19 cents.
Exact Sciences (EXAS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Exact Sciences Corporation (NASDAQ:EXAS ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants Aaron Bloomer - Chief Financial Officer Derek Leckow - Vice President of Investor Relations Kevin T. Conroy - Chairman of the Board & CEO Conference Call Participants Andrew Frederick Brackmann - William Blair & Company L.L.C.
Exact Sciences (EXAS) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.09 per share a year ago.